PMID- 19422735
OWN - NLM
STAT- MEDLINE
DCOM- 20100921
LR  - 20151119
IS  - 1743-1328 (Electronic)
IS  - 0161-6412 (Linking)
VI  - 32
IP  - 2
DP  - 2010 Mar
TI  - Selegiline is an efficient and potent inducer for bone marrow stromal cell 
      differentiation into neuronal phenotype.
PG  - 185-93
LID - 10.1179/174313209X409016 [doi]
AB  - OBJECTIVE: Bone marrow stromal cells (BMSCs) were documented as a feasible 
      candidate for cell therapy. Several protocols with one or more steps, using 
      different chemicals, were used for inducing BMSCs differentiation into neuronal 
      phenotype. Many of these chemicals were reported to be of mutagenic, teratogenic 
      or carcinogenic properties. The purpose of this work was to evaluate the neuronal 
      inductivity of selegiline to BMSCs. METHODS: Selegiline was used to induce BMSCs 
      following pre-induction with beta-mercaptoethanol and retinoic acid. The neuronal 
      phenotype was evaluated using antineurofilament 200, neurofilament 68, anti-Map-2 
      and synapsin I antibodies. In addition, reverse transcription polymerase chain 
      reaction was used for the expression of brain-derived neurotrophic factor (BDNF), 
      nerve growth factor (NGF), neurotrophin 3 (NT-3), neuroligin 1 and post-synaptic 
      density protein 95 (PSD-95). RESULTS: The result of the work showed that the 
      induced BMSCs were immunoreactive for neurofilaments 200 and 68. Moreover, 
      anti-Map-2 and synapsin I antibodies showed a structure morphologically 
      consistent with synapses. Reverse transcription polymerase chain reaction showed 
      that the induced BMSCs could express BDNF, NGF, NT-3, neuroligin 1 and PSD-95. 
      The time course used was 1, 3, 6, 12, 24, 36 and 48 hours, and the percentages of 
      neurofilament 200 immunoreactive cells were analysed using the logistic growth 
      curve. DISCUSSION: The results showed that selegiline was efficient and a potent 
      inducer for BMSCs into neuronal phenotype, which can be used in the cell therapy 
      in neurodegeneration and traumatic nervous tissue injuries.
FAU - Ghorbanian, Mohammad Taghi
AU  - Ghorbanian MT
AD  - Department of Anatomical Sciences, School of Medical Sciences, Tarbiat, Modares 
      University, Tehran, Iran.
FAU - Tiraihi, Taki
AU  - Tiraihi T
FAU - Mesbah-Namin, Seyed A
AU  - Mesbah-Namin SA
FAU - Fathollahi, Yaghoub
AU  - Fathollahi Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20090506
PL  - England
TA  - Neurol Res
JT  - Neurological research
JID - 7905298
RN  - 0 (Neuroprotective Agents)
RN  - 2K1V7GP655 (Selegiline)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/*cytology/*drug effects/physiology
MH  - Cell Differentiation/*drug effects/physiology
MH  - Cells, Cultured
MH  - Neurons/cytology/*drug effects/physiology
MH  - Neuroprotective Agents/*pharmacology
MH  - *Phenotype
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Selegiline/*pharmacology
MH  - Stromal Cells/cytology/drug effects/physiology
EDAT- 2009/05/09 09:00
MHDA- 2010/09/23 06:00
CRDT- 2009/05/09 09:00
PHST- 2009/05/09 09:00 [entrez]
PHST- 2009/05/09 09:00 [pubmed]
PHST- 2010/09/23 06:00 [medline]
AID - ner1630 [pii]
AID - 10.1179/174313209X409016 [doi]
PST - ppublish
SO  - Neurol Res. 2010 Mar;32(2):185-93. doi: 10.1179/174313209X409016. Epub 2009 May 
      6.